Dry Eye

Mile Brujic, OD, FAAO, shares an overview of his AOA 2023 presentation, which covered 12 new treatments all optometrists should know about.

When dry eye treatments are not working for your patient’s symptoms or the anterior segment exam looks normal, you must ask yourself: What if the symptoms are secondary to a neurologic dysfunction in pain perception?

Bruder Healthcare expands their dry eye portfolio by entering a distribution agreement with AllerFocus for its Percutaneous Allergy Test.

Mile Brujic, OD, FAAO, shares an overview of his AOA 2023 presentation that discussed the pharmaceutical treatment of anterior segment inflammatory conditions.

Jessilin Quint, OD, MBA, MS, FAAO, shares the latest and greatest in the world of dry eye, from new technology to how clinicians can start in on dry eye therapy today.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

The water-free, preservative-free, anti-inflammatory drop from Novaliq, now coined Vevye, received FDA approval to treat the signs and symptoms of dry eye disease.

Since April 2022, the Dry Eye Foundation has been voicing concerns over the packaging of preservative-free drops as well as availability of noncompliant drops at online retailers.

This single-ingredient tear stabilizer from Bausch + Lomb and Novaliq could become the choice therapeutic for dry eye disease.

MIEBO, previously known as NOV03, is the first and only FDA-approved treatment for dry eye disease that targets tear evaporation.

Lucie Moore, BSc, in a presentation at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, said the study focused on identifying factors that could put patients at a higher risk for developing dry eye disease.

Data on Palatin’s formulation PL9643 indicates clinical efficacy across multiple signs and symptoms of dry eye disease without sacrificing safety and tolerability.

Selina McGee, OD, FAAO, Dipl ABO, shares highlights from her featured symposium, "Thyroid eye disease: The masquerading eye disorder," which she co-presented during the 2023 Controversies in Modern Eye Care meeting.

Laura Periman, MD, breaks down some myths and controversies in the cosmetic world in her presentation, "Ocular toxins everywhere and in everything," presented at the Controversies in Modern Eye Care meeting.

Help patients establish a daily eye care routine like the one they have for oral health.

In addition to these tips on preventing digital eye strain, it is important to implement other eye-healthy habits.

The authors conducted a prospective non-interventional study in which a self-questionnaire was used to evaluate the ocular symptoms and medical background of patients with KC and OSD who engage in chronic eye rubbing.

An important take-away was the total and central corneal staining score improving after only 2 weeks of treatment.

Recommending a nighttime eye mask and ear plugs may protect the ocular surface.

Dirty equipment and sterilization issues are among the many violations found by the FDA.

Nasal spray may fill the gaps left by artificial tears.

Women are at higher risk of eye disease than men.

A look back on what happened in optometry during the week ofMarch 27-March 31.

Investigators reported that moderate to severe Meibomian gland dysfunction (MGD) was treated successfully with a 3-week course of weekly oral azithromycin that was equivalent to a 6-week course of oral doxycyclin.

A look back on what happened in optometry during the week of March 20-March 24.

The second pivotal phase 3 data on NOV03 (perfluorohexyloctane) show that NOV30 consistently met primary endpoints for signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

Catch up on what to expect from Lumenis.

How one OD incorporated full-service dry eye treatment.

The ones you should seek out—and avoid.

BRIM Biotechnology’s BRM421 is a first-in-class regenerative peptide and could relieve signs and symptoms of dry eye disease in as little as 2 weeks.